Literature DB >> 17938505

Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management.

Atsushi Kumagai1, Christoph Reiners, Valentina Drozd, Shunichi Yamashita.   

Abstract

One of the lessons from Chernobyl's legacy on health impact beyond 20 years is not only how to detect and treat the patients with radiation-associated thyroid cancers but how to follow up those who received radioactive iodine treatment repetitively after surgery in order to monitor any recurrence/worsening and also how to predict the risk of secondary primary cancers for their lifetime period. To evaluate the possibility of second primary tumors after radioactive iodine treatment, we reviewed the reports on risks from both external and internal radiation exposure, especially at high doses during childhood through an internet service of the National Library of Medicine and the National Institutes of Health, PubMed by the end of June, 2007, together with our own experience of Chernobyl childhood thyroid cancers. Children who were internally exposed after Chernobyl accident have a long-term risk of well differentiated thyroid cancers. Once they have disease, ironically radioactive iodine ablation is one of the useful therapies after surgical treatment. Elevated risks of solid cancers and leukemia have been found in radioiodine-treated patients, however, so far precious few reports from Chernobyl thyroid cancer patient were published. To reduce the adverse effects of radioactive iodine therapy on non-target tissues, recombinant human TSH has been applied and proved effective. Period of latency of second primary cancers may be very long. Therefore patients treated with high activities of radioactive iodine, especially children cases, should be carefully followed up during their whole lifespan.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938505     DOI: 10.1507/endocrj.k07e-012

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

1.  Papillary thyroid carcinoma does not have standard course in children.

Authors:  Ibrahim Karnak; Burak Ardıçlı; Saniye Ekinci; Arbay Ozden Ciftçi; Diclehan Orhan; Gülsev Kale; Feridun Cahit Tanyel; Mehmet Emin Senocak
Journal:  Pediatr Surg Int       Date:  2011-05-24       Impact factor: 1.827

2.  Clinical experiences with radiation induced thyroid cancer after chernobyl.

Authors:  Christoph Reiners
Journal:  Genes (Basel)       Date:  2011-05-31       Impact factor: 4.096

Review 3.  A Search for Causes of Rising Incidence of Differentiated Thyroid Cancer in Children and Adolescents after Chernobyl and Fukushima: Comparison of the Clinical Features and Their Relevance for Treatment and Prognosis.

Authors:  Valentina Drozd; Vladimir Saenko; Daniel I Branovan; Kate Brown; Shunichi Yamashita; Christoph Reiners
Journal:  Int J Environ Res Public Health       Date:  2021-03-26       Impact factor: 3.390

Review 4.  Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.

Authors:  Christoph Reiners; Rita Schneider; Tamara Platonova; Mikhail Fridman; Uwe Malzahn; Uwe Mäder; Alexis Vrachimis; Tatiana Bogdanova; Jolanta Krajewska; Rossella Elisei; Fernanda Vaisman; Jasna Mihailovic; Gracinda Costa; Valentina Drozd
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-10       Impact factor: 5.555

5.  Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.

Authors:  Valentina Drozd; Rita Schneider; Tamara Platonova; Galina Panasiuk; Tatjana Leonova; Nataliya Oculevich; Irina Shimanskaja; Irina Vershenya; Tatjana Dedovich; Tatjana Mitjukova; Inge Grelle; Johannes Biko; Christoph Reiners
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-28       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.